Results 51 to 60 of about 13,388,853 (301)
Battery‐Inspired Electrochemical Synapses for Neuromorphic Applications
Battery‐ion‐inspired synaptic devices integrate diverse electrolyte systems (solid, ion‐gel, liquid) with transition metal oxides, two‐dimensional materials, and organic channels to regulate ion‐electron coupling. By tailoring ion transport and host interactions, these platforms enable controllable plasticity and energy‐efficient implementations for ...
Won Woo Lee +6 more
wiley +1 more source
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi +10 more
doaj +1 more source
A nanomodulator called L‐Arginine/lificiguat@Copper‐hollow Prussian blue@Calcium phosphate nanoparticles is constructed to launch a self‐amplifying “avalanche effect” in tumor cells. The ensuing cascade, triggered by the acidic tumor microenvironment and near‐infrared light, induces calcium overload, generates a reactive oxygen species and reactive ...
Hongmei Zhou +9 more
wiley +1 more source
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen +8 more
doaj +1 more source
Dual‐line Genome‐scale CRISPR Screening Enables Robust Target Gene Discovery
A species‐optimized CRISPR platform integrates efficient piggyBac delivery, genome‐scale sgRNA libraries, and parallel screening in two independently engineered Bactrocera dorsalis Cas9 cell lines. Cross‐line consensus analysis filters line‐specific effects, enriches candidates with reproducible in vivo phenotypes, and reveals conserved, species ...
Ziniu Li +9 more
wiley +1 more source
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
Naoko Hashimoto +7 more
doaj +1 more source
Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto +4 more
doaj +1 more source
A disease‐stage synchronized nanozyme platform is developed to treat polymicrobial sepsis by adapting its functions to changing infection environments. The system eliminates multidrug‐resistant bacteria during early infection while reducing inflammation and restoring immune balance during recovery, providing an integrated strategy for infection control
Anlai Zou +11 more
wiley +1 more source
Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [PDF]
The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect
ZHU Jing, XIE Ji, HU Xiaoxia
doaj +1 more source
DPP-4 activity was measured 24 h after administration of the respective compounds (N = 13–17 per DPP-4 inhibitor group, control N = 57; no difference was made between sham-operated rats and 5/6N groups). All drugs showed a significant inhibition of DPP-4
Berthold Hocher (311916) +8 more
core +1 more source

